Bio3 Research S.r.l. signs LOI with Innova Onlus and enters discussions with a world-class CRO regarding an equity-for-services investment.
Bio3 Research S.r.l., a private early stage development biopharmaceutical company, today announced the signing of a Letter of Intent with Innova Onlus, a non-profit organization bridging the Italian scientific and investor communities, and the opening of discussions with a world-class CRO (contract research organization) regarding an equity-for-services investment. (For further information please refer to the attachment)
Bio3 Research selected to present at The Northeast Landmark Venture Forum
Bio3 Research is pleased to announce that the company has been selected to present at the Northeast Landmark Venture Forum which will be held in Greenwich/CT on December 18th 2012. Mr. Gardini (CBO) will present Bio3 Research projects. For more information please visit http://landmark.angelgroups.net/.
Bio3 Research S.r.l., Milan – Italy, has been granted by The Hong Kong Patent Registry Intellectual Property Department the patent No. HK1069316 which claims the use of HMGB1 (High Mobility Group Box 1) binding molecules, such as antibodies, for the treatment of vascular diseases and the use of the HMGB1 protein and its fragments in Connective Tissue Remodelling (e.g. healing of wounds, burns, bedsore, cartilage repair, bone matrix reconstitution, ligaments and tendons reconstitution, rheumatoid arthritis, lupus erythematosus, psoriasis, atopic dermatitis).
The Hong Kong patent grant strengthens Bio3 Research patent portfolio in the HMGB1 field.
In addition to Hong Kong, patents have now been granted to Bio3 Research in the USA, Europe, Japan, Australia, Mexico, China, Italy and are pending (very final phase) in the USA (two divisional applications), Canada and China (one divisional application).
Bio3 Research selected to present at The New England Venture Summit
Bio3 Research is pleased to announce that the company has been selected as one of the 50 Top Innovators and has been invited to present at The New England Venture Summit 2012 which will be held in Boston Dedham on December 5th 2012 (for more information please visit http://www.youngstartup.com/newengland2012/overview.php).
Bio3 Research is glad to announce that BIOCYSAN® patent 10,583,334 has been granted in the USA by the USPTO.
The US patent grant strengthens Bio3 Research patent portfolio with BIOCYSAN®.
In addition to the USA, BIOCYSAN® patents have now been granted to Bio3 Research in Canada, Mexico (NAFTA) and also in Europe. BIOCYSAN® patent is pending (very final phase) in Japan.
Bio3 Research is glad to inform that recent (2012) clinical and experimental studies confirm the role of HMGB1 in vascular diseases and in connective tissue related pathologies (please refer to the below links).
The company has a strong IP position (11 patents granted in the USA, EU, JP, PRC, AU, MX, HK, IT and 4 still pending) covering the use of HMGB1 inhibitors and antagonists, such as antibodies, antibodies fragments, and HMGB1 fragments, for the treatment of vascular diseases comprising arterial stenosis, restenosis and atherosclerotic plaque progression and in pathologies involving the connective tissues e.g. in Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriasis.
Bio3 Research HMGB1 patents cover also the use of the HMGB1 protein as such in Connective Tissue Regeneration (e.g. wound healing, cartilage repair, bone matrix reconstitution, ligaments and tendons reconstitution).
The company is glad to confirm that official discussions with third parties for the licensing-out of the entire Bio3 Research HMGB1 IP package are progressing.
BIO3 RESEARCH LICENSING OUT ITS IP PORTFOLIO IN HMGB1 FIELD
Bio3 Research (www.bio3research.com) has entered into official discussions with third parties interested in licensing-in its HMGB1 IP package (11 patents granted in the USA, EU, JP, PRC, AU, MX, HK, IT and 4 still pending) to acquire rights to develop HMGB1Antagonists, Mabs, HMGB1 fragments to prevent Cardiovascular Disorders such as Atherosclerotic plaqueprogression, Restenosis, Arterial Stenosis and in pathologies involving the connective tissues (RA, SLE, Psoriasis). Under the license right third parties can also develop the use of the protein HMGB1 as such which has been proven to be a potential therapeutic tool in the regeneration of damaged connective tissues.
Bio3 Research continues theinternational markets activity with Biocysan® a proprietary dietary supplement based on L-Cysteineto prevent anaemia and oxidative stress in individuals suffering oflow levels of Glutathione.
Bio3 Research is glad to announce that BIOCYSAN®patent has been granted in Canada (CA 2551043).
Bio3 Research has also been granted BIOCYSAN®patent in Europe and Mexico. In the USA and Japan Biocysan® patents are still pending but are very close to their final phase of review by the relevant Patent Offices.
Bio3 Research is glad to announce that BIOCYSAN®trademark (Class 5) has been granted in Italy.
Bio3 Research has also been granted BIOCYSAN®trademark (Class 30) in Europe and in the USA and BIOCYSAN®trademark (Class 5) in the USA, Mexico, Japan, South Korea, Turkey and PRC.
Bio3 Research S.r.l., Milan – Italy is pleased to announce that Bio3 Research trademark has been registered in the USA by USPTO (registration # 4,092,757)
Bio3 Research S.r.l., Milan – Italy informs that, further to the opposition filed by the company pursuant to art. 99 EPC against the Creabilis Therapeutics European patent EP2068935 “Polymer Conjugates of Box-A of HMGB1 and Box-A Variants of HMGB1”, the European Patent Office has requested that the EP2068935 Applicant, Creabilis Therapeutics, file observations on the Bio3 Research opposition by June 20th 2012.
Bio3 Research considers the Creabilis Therapeutics patent not patentable, under art. 56 EPC because it lacks an inventive step.
EPO considered the Bio3 Research opposition relevant against Creabilis Therapeutics’ patent EP2068935.
Bio3 Research will pursue all the available options to safeguard its Intellectual Property rights including, if necessary, to challenge any patent infringement in all the appropriate jurisdictions.
Bio3 Research is glad to announce that BIOCYSAN® trademark (Class 30) has been granted in the USA by the USPTO.
Bio3 Research has also been granted BIOCYSAN® trademark (Class 30) in Europe and BIOCYSAN® trademark (Class 5) in the USA, Mexico, Japan, South Korea, Turkey and PRC.
Bio3 Research S.r.l. (Milan/Italy) is pleased to announce that it has completed its acquisition of the full ownership of all the patents in its portfolio concerning HMGB1 (High Mobility Group Box 1). HMGB1 patents have been granted to Bio3 Research in the USA, Europe, Japan, Australia, Mexico, PRC, and Italy. Other patents are still pending (at a very final stage) in the USA (two divisionals), in Canada, and in the PRC (one divisional application). With this acquisition, the company has gained a dominant position in the field of HMGB1 since its patent portfolio covers the use of HMGB1 antagonists [e.g. antagonists of any nature, antibodies, antibody fragments, four-way DNA, HMGB1 fragments such as Box-A and its variants, etc.] for the treatment of vascular diseases (including restenosis, arterial stenosis, and atherosclerotic plaque progression), and the use of the HMGB1 protein and its fragments [such as Box-A and its variants, etc.] in Connective Tissue Remodelling (e.g. healing of wounds, burns, and bedsores, cartilage repair, bone matrix reconstitution, ligament and tendon reconstitution, rheumatoid arthritis, lupus erythematosus, psoriasis, atopic dermatitis, etc.).
Bio3 Research S.r.l. is glad to announce that Biocysan®, L-Cysteine pulse release dietary supplement, is available via ecommerce (please visit the official website www.biocysan.com )
Bio3 Research S.r.l., Milan – Italy, has been granted by the Chinese Patent Office the patent No. 02806567.0 which claims the use of HMGB1 (High Mobility Group Box 1) binding molecules, such as antibodies, for the treatment of vascular diseases and the use of the HMGB1 protein and its fragments in Connective Tissue Remodelling (e.g. healing of wounds, burns, bedsore, cartilage repair, bone matrix reconstitution, ligaments and tendons reconstitution, rheumatoid arthritis, lupus erythematosus, psoriasis, atopic dermatitis).
The Chinese patent grant strengthens Bio3 Research patent portfolio in the HMGB1 field.
In addition to PRC, patents have now been granted to Bio3 Research in the USA, Europe, Japan, Australia, Mexico, Italy and are pending (very final phase) in the USA (two divisional applications), Canada and PRC (one divisional application).
Bio3 Research S.r.l., Milan – Italy, has recently been granted by the Japanese Patent Office the patent No. 2002-573044 which claims the use of HMGB1 (High Mobility Group Box 1) inhibitors and antagonists, such as antibodies, antibodies fragments, and HMGB1 fragments, for the treatment of vascular diseases comprising arterial stenosis and restenosis.
This patent also covers the use of the HMGB1 protein in Connective Tissue Regeneration (e.g. wound healing, cartilage repair, bone matrix reconstitution, ligaments and tendons reconstitution, rheumatoid arthritis, Lupus Erythematosus, Psoriasis, Atopic Dermatitis).
The Japanese patent grant strengthens Bio3 Research patent portfolio in the HMGB1 field.
In addition to Japan, patents have now been granted to Bio3 Research in the USA, Europe, Australia, Mexico, Italy and are pending (very final phase) in Canada and China.
HMGB1 is also recognised to have an important impact in immunology and epilepsy.
Bio3 Research S.r.l., Milan – Italy, has submitted to the European Patent Office observations pursuant to Art. 99 EPC concerning the patentability of the invention claimed in EP 2068935 “Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1”, in the name of Creabilis Therapeutics.
Bio3 Research S.r.l., Milan – Italy, has submitted to the European Patent Office observations pursuant to Art. 115 EPC concerning the patentability of the invention claimed in EP 1919979 “Polymer Conjugates of K-252A and Derivatives Thereof”, in the name of Creabilis Therapeutics. (For further details please refer to the attachment)
June 3rd, 2011:
Bio3 Research is glad to announce that a Distribution Agreement for BIOCYSAN™ has been entered into with the Swiss Company SURPASS Technology AG for Serbia, Macedonia (FYROM), Romania, Georgia and Azerbaijan.
In advanced kidney disease, anemia becomes a significant problem that many people face. On dialysis, then treatment of anemia with Erythropoietin Stimulating Agents (ESA) and iron are a standard of care. In this episode we look at traditional methods which can help. How are ESAs used? What is the role of oxidative stress in anemia? What about low glutathione levels? During this hour, we will be joined by Dr. Francisco Paolo Pilato, President, Founder and CEO of Bio3Research. He will discuss with us the use of the dietary supplement BIOCYSAN and its role in anemia management and in many chronic diseases.
Bio3 Research S.r.l. is pleased to announce that the company has granted to V.I.Pharma International s.a. (Athens, Greece) exclusive rights to distribute the dietary supplement Biocysan™ in Bulgaria and Cyprus.
Bio3 Research S.r.l. announced today that the company has granted to V.I.Pharma International s.a. (Athens, Greece) the exclusive distributorship for the dietary supplement Biocysan™ in Greece. (For further details please refer to the attachment).
January 20th, 2011: Bio3 Research S.r.l. is glad to announce that on January 13th 2011, the Italian Ministry of Health has granted the Free Sale Certificate for the Dietary Supplement BIOCYSAN®.
January 14th, 2011: Bio3 Research S.r.l. is pleased to announce the forthcoming launch (mid March 2011) in the USA, via ecommerce, of the proprietary Dietary Supplement BIOCYSAN® (L-Cysteine 700 mg oral route – Pulse Release), a product aimed at alleviating ANEMIA symptoms in individuals suffering of impaired Glutathione synthesis.
For further information please visit BIOCYSAN® official websitewww.biocysan.com
Bio3 Research s.r.l. has exercised an option for exclusive license from ProtElix, Inc. d/b/a Protelica for mimic-antibody antagonists to HMGB1 under development for therapeutic use in cardiovascular disorders. Please refer to the attachment.
May 6th, 2010: Bio3 Research Patent Granting in Mexico
Bio3 Research S.r.l., Milan – Italy, has recently been granted from the Mexican Patent Office the patent No. PA/a/2003/008364 which claims the use of HMGB1 (High Mobility Group Box 1) inhibitors and antagonists, such as antibodies, antibodies fragments, HMGB1 fragments, inhibitors in general, for the treatment of vascular diseases comprising atherosclerotic-plaque progression and/or restenosis.
The captioned patent covers also the use of HMGB1 protein in Connective Tissue Regeneration.
The granted Mexican patent strengthens Bio3 Research patent portfolio in the HMGB1 field.
Further to Mexico, patents have now been granted in the USA, Europe, Australia, Italy and are pending (very final phase) in Canada, Japan and China.
April 22nd, 2010:
Bio3 Research S.r.l. announced today that the company has filed with the Italian Healthcare Ministry for Free Sale Certificate (FSC) clearance in Italy for the use of oral cysteine (Biocysan™) as Neutraceutical in people with increased needs of cysteine. Please refer to the attachment.
March 16, 2010:
Bio3 Research Patent Granting in the USA
Bio3 Research has recently been granted from USPTO the US patent # 10/471,641 which claims the use of HMGB1 (High Mobility Group Box 1) inhibitors and antagonists, such as Abs and four way DNA, for the treatment of Cardiovascular Disorders (e.g. Restenosis and Arterial Stenosis).
8th Cytokines & Inflammation Conference- San Diego - January 28-29, 2010.
Bio3 Research has presented an oral speech and the relevant poster on: HMGB1 in wound healing. Bio3 Research has also posted a poster on Mimic Abs HMGB1 antagonists. Please refer to the attachment.
October 9, 2009: Bio3 Research Inc. (Hayward/CA/USA), a fully owned subsidiary of Bio3 Research s.r.l. (Milano/Italy) is pleased to announce the beginning of the in house production of HMGB1 protein from E.Coli (>95% pure) for the use of the protein in preclinical development programs.
Further to a collaboration with The Scripps Institute (La Jolla/CA/USA) via Bio3 Research Inc. partner Protelica, Bio3 Research Inc. has also started the production of HMGB1 protein from green source.
September 21, 2009:
Bio3 Research Inc. (Hayward, CA, USA) and Protelica Inc. (Hayward, CA, USA) have published, at the conference Beyond Antibodies (San Diego September 21-23 , 2009) a poster regarding the development activities performed in the field of Mimic Abs anti-HMGB1 (second generation antibodies). Please refer to the attachment.
April 2, 2009: Bio3 Research S.r.l. (Milano – Italy), is pleased to announce the positive preclinical studies outcome (conducted by the CRO Bio-Quant Inc. La Jolla/CA) obtained with HMGB1 in wound healing in mice and pigs (Vehicle and PDGF as control) which confirms the protein high potential in tissue remodelling. HMGB1 project has demonstrated in-vitro and in-vivo the dual ability of the protein to accelerate the wound healing process and to control the remodelling of collagen and fibroblasts.
Bio3 Research has also tested in animals (rabbits) HMGB1 for its use in cartilage repair with encouraging results.
September 15, 2008:
The Mexican Patent Office has granted Bio3 Research S.r.l. a patent for the use of oral cysteine (Biocysan™) in hemodialysed patients (End Stage Renal Disease – ESRD). For more details please refer to the herewith pdf file.
June 12, 2008:
Bio3 Research S.r.l. (Milano – Italy), is pleased to announce the official opening of a Californian subsidiary, located in Hayward.
The opening of Bio3 Research Inc., will enable the company to expand its activities in one of the most dynamic cluster, Silicon Valley, synonym of technology and innovation, which represents the ideal place for biomedical firms specialized in the areas of R&D in the life sciences and biopharmaceuticals, with the common purpose of improving the quality of human health and life.
Bio3 Research with the presence of a Californian subsidiary will also strengthen its strategic collaboration with two Californian based companies, Protelix Inc. and SynGen Inc., for the development of SiRNA HMGB1 specific and Mimic antibodies against HMGB1 in cardiovascular disorder related to HMGB1.
Other alliances will be worked out to develop HMGB1 in connective tissues regeneration.
A presence in the USA will also enable Bio3 Research to develop its proprietary compound Biocysan (cysteine) in the prevention of severe anemia in hemodialysed patients.
November 26, 2007:
The European Patent Office has granted Bio3 Research S.r.l. a patent for the use of oral cysteine (Biocysan™) in hemodialysed patients - End Stage Renal Disease. For more details please refer to the herewith pdf file.
May 30, 2007:
The British Medicines and Healthcare products Regulatory Agency (MHRA) has authorizedCreabilis Therapeutics, Italy,to carry out Phase I Clinical Trial in the UK for CT327 (Pegylated K252A) for the topical treatment of Psoriasis .The proprietarycompound is under development at Creabilis Therapeutics S.p.A laboratories (Italy). Creabilis Therapeutics has granted Bio3 Research s.r.l exclusive worldwide business development rights for CT327 licensing out.
March 15, 2007:
Bio3 Research S.r.l. has been granted by the Australian Patent Office a patent in the field of cardiovascular diseases related to HMGB1 over-expression and for the use of HMGB1 protein in connective tissue regeneration. For more details please refer to the herewith pdf file.
November 30, 2005:
Bio3 Research and Creabilis Therapeutics sign research agreements with Cephalon, Inc. Research will focus on potential new treatments for psoriasis and restenosis. For more details please refer to the herewith pdf file.
March 17, 2005:
The patent "HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases" has been granted in Italy.
January 26, 2005: Bio3 Research PCT filing in the field of Restenosis (Proliferation Patent)
A patent application has been filed under the PCT entitled "HMGB1 Antagonists and Inhibitors to prevent Endothelial and SMC proliferation".
January 21, 2005: Bio3 Research PCT filing in the field of Atherosclerosis
Bio3 Research has filed a patent application, in co-ownership with Prof. Marco Bianchi, Group Leader, Chromatin Dynamics Unit, San Raffaele Scientific Institute (Milan - Italy), in Italy under the title "HMGB1 protein inhibitors and/or antagonists inhibiting the pathogenesis and progression of the Atherosclerotic disease".
December 17, 2004: Bio3 Research PCT filing in the field of End-Stage Renal Disease.
Bio3 Research has filed a patent application under the PCT claiming the use of a specific amino acid to decrease anemia in end-stage renal disease (ESRD) patients.
August 2, 2004: Bio3 Research - Creabilis Therapeutics Licensing agreement in the field of Vascular Disorders and Restenosis
Bio3 Research has entered into a Cross-License agreement with Creabilis Therapeutics, an Italian drug discovery and development company by granting Creabilis Therapeutics exclusive rights to develop and exploit Bio3 Research four way DNA as HMGB1 antagonist in the cardiovascular area. In turn Bio3 Research has obtained from Creabilis Therapeutics, an exclusive worldwide license of certain products, such as short duplex bent DNA, bent PNA, DNA/PNA hybrids, DNA/PNA chimeras (coded CT400 series), under development by Creabilis Therapeutics in the cardiovascular field under Creabilis Therapeutics patent "Therapeutic agents for the treatment of HMGB1-related pathologies".
August 2, 2004: Bio3 Research - Creabilis Therapeutics joint patent filing in the field of Restenosis (CT301/R)
Bio3 Research and Creabilis Therapeutics have jointly filed a patent application for the use of the compound coded CT301/R in restenosis. CT301/R, a small liposoluble molecule, has a potent indirect inhibiting effect on HMGB1, resulting in anti-proliferative and anti-migration effects on BASMC and BAEC cells. Bio3 Research has worldwide exclusive licensing-out rights.
August 2, Bio3 Research - Creabilis Therapeutics agreement for the promotion of a compound (coded CT301/P) under development at Creabilis Therapeutics for the topical treatment of Psoriasis
Bio3 Research and Creabilis Therapeutics have entered into a strategic alliance for the promotion and licensing-out of CT301/P, a compound under development for the topical treatment of psoriasis. Under this agreement, Bio3 Research will assist Creabilis Therapeutics in strategic marketing, business development and licensing-out activities.
May 14, 2004: Worldwide license of the polymer free Drug Eluting Stent Endostent from the Swiss company Endosense.
Endosense, a Swiss medical device company engaged in the development of devices for the treatment of vascular disorders, has granted Bio3 Research a worldwide semi-exclusive license for their proprietary polymer free drug-eluting stent Endostent.
February 3, 2004: Bio3 Research patent application filing in the field of Restenosis
Bio3 Research has filed an Italian priority application for a patent under the title "HMGB1 Antagonists and Inhibitors to prevent Endothelial and SMC proliferation". This patent is the result of a collaboration established with Prof. Marco Bianchi, Group Leader, Chromatin Dynamics Unit, San Raffaele Scientific Institute (Milan - Italy), internationally renowned in the field of HMGB1.
September 15, 2003: Bio3 Research Nationalization Phases undertaken for the PCT WO 02/074337 in the field of Restenosis
Bio3 Research has undertaken the nationalization phase in USA, EU, JP, Canada, Australia, China for the patent application "HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases".
July 22, 2003: Termination of the agreement between Bio3 Research and Lay Line Genomics (LLG).
Bio3 Research announces the termination of its agreement with Lay Line Genomics. Under the collaboration established in the year 2001 Bio3 Research helped LLG to enter into service and non-exclusive license contracts with leading pharmaceutical companies for the use of LLG's transgenic anti-NGF mouse AD11.
September 26, 2002: Bio3 Research PCT filing in the field of Restenosis
Bio3 Research has filed a patent application under the PCT entitled "HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases".
October 28, 2001: Bio3 Research has entered into an agreement with Lay Line Genomics.
Under the agreement Bio3 Research will assist Lay Line Genomics (LLG), an Italian company engaged in the development of new drugs and innovative therapies for Alzheimer's and other neurological diseases, in licensing out the use of LLG's anti-NGF mouse AD11.
